Collectively, our documentation that MSI2 affects CLL-cell growth and survival and correlates with worse clinical course and outcome suggests that this molecule and its pathway are potential therapeutic targets. The gene discussed is MSI2; the disease is B-cell chronic lymphocytic leukemia.